发布于: 雪球转发:0回复:1喜欢:0
$ImmunoGen(IMGN)$
First Patient Dosed in FORWARD I Phase 3 Study of Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer,1.26公布

全部讨论

2017-01-28 05:03

Charles Morris, MBChB, MRCP, Executive Vice President and Chief Development Officer, is leaving the Company effective September 2", 2016年的事,技术牛人们纷纷走人,不是好现象啊!


"Effective January 1, 2017, Dr. John M. Lambert, Executive Vice President Emeritus and Distinguished Research Fellow, went onto part-time status". 貌似非好事